LiveChain Inc (PK) (LICH) 시세

Something has to give soon, I think we get good news like you said in the 2nd quarterly and something perhaps in the Ist that is due..

Venkat is bullish on the Biotech market. Hopefully good news coming soon for LICH!

https://www.linkedin.com/posts/venkatnelabhotla_biotech-pharma-innovation-activity-7316952095855677441-n85p?utm_source=share&utm_medium=member_desktop&rcm=ACoAAADuH9cBtLM5NnMjNhx-1utp_aFftKbtKTc

https://www.linkedin.com/posts/venkatnelabhotla_indiagrowth-economicreforms-globaltrade-activity-7317208237521412096-baHP?utm_source=share&utm_medium=member_desktop&rcm=ACoAAADuH9cBtLM5NnMjNhx-1utp_aFftKbtKTc

Attorney letter just verifies the 2024 filings were reviewed by them. It is required to have one each year to remain pink. Vyome still owes Q1 filing (Sept 1 Dec 31 2024). Once they submit that we are pink again. I assume that is coming soon because I've been pestering Venkat about getting current. I think the Q2 filing (Jan 1 - March 31 2025) will be revealing. I assume we wont see that for a little while.

Anything positive

Attorney letter posted for 2024 filings
https://www.otcmarkets.com/stock/LICH/overview

Hey Thunder, hope you've had a chance to delve into my novel some. It received 4 out of 5 star review at Online Book Club. I am getting some editing done now and with resubmit the book to the world in June. I did release a 14-song all-original soundtrack that accompanies the book. It is available for free listening on Soundcloud, Spotify, and YouTube Music. Just search for Commander Hemp Poaching the Poachers and tge album should pop up... my song Call of the Wild is the opening track. My songs have been getting picked up on pkaylusts in Europe and South America and USA.

Hey Thunder, hope you've had a chance to delve into my novel some. It received 4 out of 5 star review at Online Book Club. I am getting some editing done now and with resubmit the book to the world in June. I did release a 14-song all-original soundtrack that accompanies the book. It is available for free listening on Soundcloud, Spotify, and YouTube Music. Just search for Commander Hemp Poaching the Poachers and tge album should pop up... my song Call of the Wild is the opening track. My songs have been getting picked up on pkaylusts in Europe and South America and USA.

Hellooooooooooooooooooooooooooooo

Nm

Radio Silence

I predict that Next Thursday/Friday we get the quarterly plus additional news imo

Gracious... GG, aka Dr. J

Called Vyome, got a local ringtone so Venkat is probably back in the States now, I left a message

HEY GANG, here is the link to my new 14-song album, the all-original soundtrack that accompanies my eco-fiction-thriller novel Poaching the Poachers... here is the Soundcloud link to the album you can hear for free and turn it up! https://soundcloud.com/search?q=commander%20hemp%20poaching%20the%20poachers

He is still overseas, most likely getting their plan together

Interesting LinkedIn article by Venkat regarding IPO's

Venkat Nelabhotla
The biotech sector in 2025 is showing encouraging signs of recovery, with a mix of IPO activity, follow-on offerings, and M&A deals shaping the industry’s trajectory. Companies like Metsera, Sionna Therapeutics, and Aardvark Therapeutics have successfully gone public, while Odyssey Therapeutics and HaemaLogiX are preparing their IPOs. Although investor sentiment remains selective, favoring companies with strong differentiation and de-risked profiles, the steady flow of public offerings signals growing confidence in biotech innovation. The growing integration of AI in drug discovery and clinical development is also accelerating investor interest, as companies leverage machine learning to de-risk pipelines and enhance R&D productivity. While the pace of IPOs is still measured compared to the peak years, firms with compelling science and strategic execution are finding their way to the public markets (xtalks.com, fiercebiotech.com).

On the M&A front, while large-scale deals have faced some delays due to economic conditions and regulatory scrutiny, companies like AstraZeneca are actively pursuing strategic acquisitions, such as its recent $1 billion deal for EsoBiotec to enhance its cancer pipeline. Analysts estimate total biopharma M&A deal values could reach between $50 billion and $90 billion in 2025, with the top 25 firms holding over $1.3 trillion in “firepower” for acquisitions. AI-driven biotech startups are becoming increasingly attractive targets, as major pharma players seek to integrate cutting-edge computational biology and predictive analytics into their drug development strategies (iqvia.com, labiotech.eu). While uncertainties persist, the fundamentals of the industry remain strong, setting the stage for a measured but optimistic outlook for the rest of 2025. Looking forward to seeing how the sector evolves in the coming months!

this week is shot

looks like you can be barely breathing and stay on the Pink Limited tier by verifying your profile every 12 months (last done here 11/2024) and filing an Annual report within the previous 16 months

alternative reporting standards---page 2 pink limited

https://www.otcmarkets.com/financialReportViewer?symbol=UBQU&id=393724

see the pink limited box at the bottom in the alternative reporting row

https://www.otcmarkets.com/files/15c2-11%20Tier%20Chart.pdf

Does anyone know how long filings can be late before we get sent to expert market? 

Nope not me

Yeah, the silence is deafening! Guess that was you the scooped the 0093's?

Contemplating on whether to pick up some more shares at .0047...need to transfer some cash though...with this delay I feel some news is definitely coming...by mid-April for sure if not sooner... this type of delay has never happened on posting a quarterly (I think) ... I realize Venkat is out of the country, but if he was just going to carry the shell over to the next quarter, he would have gotten the minimal paperwork out of the way by now imo

Still hoping that Alyssum Therapeutics takes over the Shell.

https://www.linkedin.com/in/shiladitya-sengupta-8441bb1/recent-activity/reactions/

Yes, agree. Im seeing explosive growth in IPO's the past few weeks, Biotech startups are going public, and seeing especially big growth in India investment. I'm sure there is a plan for this shell.

Something has to be coming here with this long delay in the quarterly imo

Latest post from Venkat on the bright future of Vyome. I'm not sure how LICH will unfold, but if Vyome becomes a major biotech player, I'm sure LICH will be part of the success story in some way.

https://www.linkedin.com/feed/update/urn:li:activity:7309165306491375617/
The immuno-inflammatory disease space is witnessing rapid growth, driven by major FDA approvals and a surge in novel drug development. AbbVie’s SKYRIZI® (risankizumab-rzaa) was recently approved for ulcerative colitis, expanding its indications across multiple immune-mediated diseases, while Eli Lilly’s Omvoh secured expanded FDA approval for Crohn’s disease, reinforcing the potential of targeted drugs. With next-gen biologics, small-molecule therapies, and precision-based treatments reshaping the industry, the market is poised for significant expansion. The global anti-inflammatory drugs market is expected to grow from $130.7B in 2024 to $272.35B by 2033 (CAGR: 8.5%), while the immunology market is projected to reach $254.23B by 2032. Additionally, the autoimmune disease therapeutics market is set to hit $200B by 2031, driven by increasing disease prevalence and innovation.

With its cutting-edge pipeline of therapies targeting high-unmet-need immuno-inflammatory diseases, Vyome Therapeutics is positioned in the right space at the right time. By leveraging the US-India innovation corridor, Vyome is driving progress in a cost-efficient manner while maintaining world-class R&D and execution. With its proprietary platforms and clinical-stage programs, Vyome Therapeutics, Inc. is focused on delivering first- and best-in-class solutions that can transform patient care. As the industry accelerates toward precision-based treatments, the opportunities are vast, and Vyome is fully aligned with this momentum. Exciting times ahead for biotech and immuno-inflammatory innovation!

Haha...sad and true...need to get things rolling here soon

https://images.app.goo.gl/QttDQQhn69atuaD48

Venkat is in India, I don't see anything coming until April

Not a share bought in two weeks, something's gotta give

He has been posting a lot on LinkedIn the past week. Sometimes he goes a month without posting, so seems he is a good mood lately. Maybe he's on vacation, or things are going well with business.
https://www.linkedin.com/in/venkatnelabhotla/recent-activity/reactions/

Left a message for Venkat on the company voicemail today...sounds like an overseas ringtone

Perhaps LICH will have something to do with AI technology? Venkat seems really excited about AI in biotech.

AI is transforming drug discovery—accelerating research, predicting proteins, and unlocking treatments faster than ever. The future of medicine is here! #AI #Biotech @VyomeTx https://t.co/p0eL0NDAIU— Venkat Nelabhotla (@newvenkat) March 14, 2025

Here is my new rally song to the UK patriot Tommy Robinson...it's called Free Tommy and it is a real ram jam...enjoy a listen and give a like!

I would think we have to hear something soon...they are a month past due on the quarterly

Not sure either. Nasdaq has strict RS rules now. But since it is a merger and they would be changing the name from RSLS to HIND perhaps they can do another RS to keep from being delisted?

Looks like they need a 10/1 RS from here. To keep them way above the threshold. That ship is sinking quick. Looks like trouble to me and vyome should rethink unless they want to just kill legacy with a RS then take over? Who knows..

If Nasdaq delists RSLS, they would have to move to OTC. Vyome would have been better off using LICH. Maybe Venkat is realizing that and preparing for it? Hence the increased AS's.

Maybe that's why Venkat went back to India.

Try to convince iron pillar capital or someone else to go public with them. I know there was a shareholder revolt over there at rsls

Rsls is in the toilet, now an obvious dilution/RS scam. Venkat would be a fool to continue with the merger. Better off getting this shell fixed up.

This week is shot...

Meanwhile I am dumping hundreds in the recording studio...come on Venkat! Let's do this!

Stalemate, just as I expected. Seems like no trading till new developments.

Between a bid to low and ask to high…….im done buying, till we get some vol
and bulk offers lower…

But, we Wait…….and wait…..and wait

This is the latest Venkat has ever delayed the quarterly imo...I think some action is coming

Yep I think you be correct, mon! Soon come!

Maybe he went back to finalize a deal for the shell?

Who knows….the beat goes on…

I tried calling him but no luck. I'm getting the India ring tone so he is traveling.

I think everything will hit at once shortly.
- Attorney Letter
- Q1 filing
- OTC site updated with new SS
- Insight into why AS was increased (who, what, where, when, why)

Venkat dragging his feet again on the filings...hopefully for a good reason

Please change the word "because" to 'thus' thanks

sorry been away, Charlas Schwab and others won't participate until FEC rule for not filing on time lifts...15c2-11...so our vol is not true because we don't have a valid sample for RSI.....

Just a joke referring to we have no news...but soon come I think